Podcasts about ons

We weten allemaal wat een martelaar is. We hebben de hartverscheurende verhalen gehoord over de heldhaftige mannen en vrouwen die voor Christus zijn gestorven. Maar er bestaat ook een ander soort martelaar die niet zo moedig en nobel is —iemand die voortdurend zich beklaagt en die altijd bereid is zijn pijn te delen met iedereen die het maar wil horen. Dit soort martelaar wil aan iedereen laten weten welke opofferingen ze hebben gedaan in hun leven. We vallen makkelijk in deze "martelaars valkuil." We beginnen ons dienstbaar op te stellen naar onze familie en vrienden en genieten hiervan. Maar na een tijdje begint ons hart te veranderen en gaan we er iets voor terugverwachten. Uiteindelijk hebben we niet meer het hart van een dienaar. Ons gedrag verzuurt en al snel komen we erachter dat we verstrikt zijn geraakt in zelfmedelijden. We zijn een martelaar geworden. In de Bijbel staat te geven zonder dat je je linkerhand laat weten wat je rechterhand doet. Met andere woorden, God wil dat we dienen en geven zonder dat het ons uitmaakt of mensen het merken of ons erkennen. Ben je in deze "martelaars valkuil" gevallen? Als dit zo is, vraag God je Zijn liefde te geven zodat je onzelfzuchtig kunt geven zonder dat je je druk maakt om de waardering hiervoor.

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukIn this bonus episode, I spoke with Ed West about the new data indicating that British citizens are emigrating in much larger numbers than anyone realised. We also spoke about how emigration has shaped the Anglosphere and the proposed reforms to the asylum system. Discussed in the episode:* ONS revised emigration estimates – https://www.ons.gov.uk/peoplep…

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Zoals een perfecte techniek de sleutel is tot mentale kracht, kunnen nederlagen fungeren als springplank naar succes. Dat zegt coach Martin van der Brugghen in deze uitzending van de NL Tennis Podcast. Van der Brugghen reflecteert op zijn werk met bekende Nederlandse speelsters zoals Kiki Bertens en Suzan Lamens. Hij deelt ook inzichten over het omgaan met de mentale druk in topsport, de rol van ouders en zijn ambities voor de toekomst van zijn pupillen. De NL Tennis Podcast wordt gepresenteerd door Marcella Mesker en Jan-Willem de Lange. De titelmuziek is van Anthony Vega. De NL Tennis Podcast wordt onder meer verspreid via de nieuwsbrief van PassaTennis. Reageren op deze podcast? Je vindt ons op X: @NLTennisPodcast. Instagram: @nltennispodcast. Ons mailadres is nltennispodcast@gmail.com.

Ons kan teen sonde stry, want Jesus maak ons vry. 

Ons lees vandag saam uit Romeine 7:1-6

Economics editor Michael Simmons and Yvette Cooper's former adviser Danny Shaw join Patrick Gibbons to react to the Home Secretary's plans for asylum reform. Shabana Mahmood's direct communication style in the Commons yesterday has been praised by government loyalists and right-wingers alike, but her plans have been criticised by figures on the left as apeing Reform. Will her calculated risk pay off and how will success be judged?Plus, as ONS migration figures are revised – again – Michael restates his appeal for more reliable data. And how could migration data affect the budget next week?Produced by Patrick Gibbons.Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcasts.Contact us: podcast@spectator.co.uk Hosted on Acast. See acast.com/privacy for more information.

Wat zit er in De 7 vandaag?Ons land loopt tientallen, zo niet honderden miljoenen euro's mis door niet goed genoeg te speuren naar crimineel cryptogeld. Dat blijkt uit een onderzoek van onze redactie.Berkshire Hathaway, het fonds van meesterbelegger Warren Buffett, investeert zwaar in Alphabet, het bedrijf boven Google. Gelooft Buffett dan niet in de AI-bubbel?En supermarktketen Lidl sluit openingen op zondag voorlopig uit. Eerst moet de politiek de paritaire comités hervormen. We praten in deze podcast met de CEO van Lidl België. Host: Bert RymenProductie: Roan Van EyckSee omnystudio.com/listener for privacy information.

Die VSA weier blykbaar nou ook om die G20-verklaring te onderteken. Ons vra of dit die beraad se uitkoms sal verswak. Talle organisasies hou 'n beraad as teenvoeter vir die G20 onder die vaandel, We, the 99 percent... Kommer oor die vyf sluise wat gister by 'n propvol Vaaldam oopgemaak is.

Send us a text1 Johannes 3:8 wie aanhou sonde doen, behoort aan die duiwel, want die duiwel hou van die begin af aan met sondig. En die Seun van God het juis gekom om die werk van die duiwel tot niet te maak. ‘Boos', is 'n sterk woord. Daar is nie baie dinge in ons lewens wat ons as boos sou bestempel nie. ‘Boos' pas by 'n moordenaar, of 'n kindermolesteerder, nè? Maar dinge in ons eie lewens? Nee, nouja, nie regtig nie.En tog kan ons almal terugkyk na 'n paar besonder slegte dinge wat ons gedoen het – miskien is daar een of twee wat nog steeds in jou lewe voorkom. Dink aan mans wat dikwels onnadenkend hard met hul vrouens praat, en dag na dag daardie kosbaarste verhouding vernietig.Mense in die werkplek wat spog en die krediet neem vir wat ander gedoen het. Ons kan 'n lys, so lank soos môre heeldag, aframmel van gewone, alledaagse dinge wat eintlik, gegewe hul vernietigende impak, as ‘boos' bestempel behoort te word.1 Johannes 3:8 ...wie aanhou sonde doen, behoort aan die duiwel, want die duiwel hou van die begin af aan met sondig. En die Seun van God het juis gekom om die werk van die duiwel tot niet te maak.God se siening is baie duidelik en ek dink ons sal met Hom saamstem dat ons sonde boos is. Hy draai nooit doekies om nie, Hy verbloem nie die waarheid nie. Maar die goeie nuus van die Evangelie van Jesus Christus is dat Hy gekom het om die duiwel se werk te vernietig.Met ander woorde, die Evangelie verplaas en vernietig die boosheid wat ons van binne-af aanval.Maar hoe werk dit in die praktyk? Wat is die kern van die saak wat van toepassing op ons lewe is? Wanneer ons Jesus in ons lewens toelaat, nie as 'n lekker en gerieflike toevoeging nie, maar as die Een vir wie ons leef, as die Here van ons lewens ... is dít wat Hy doen. Hy vernietig die duiwel se werk van binne.Dit is immers waarvoor Hy gekom het.En dis God se Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Het Nederlands Elftal heeft zich, als je dit luistert, hopelijk geplaatst voor het WK, maar vanaf de roze wolk is de opvolging van Koeman nú al onderwerp van gesprek. Verder hoop iedereen op het (als we Dick een beetje inschatten) toch een-na-laatste kunstje van Advocaat en is Halfgod Troy Parrott is minstens tien keer zo goed als Mexx Meerdink. Welkom bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast hebben Snijboon, Tim en Pepijn het over alle zin en onzin rondom het interlandweekend.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Die ANC ontken dat daar 'n poging is om sy president, Cyril Ramaphosa, uit die kussings te lig. Amerika se tariefkwytskeldings op talle landbouprodukte word wyd verwelkom. Ons praat met 'n ekonoom oor Standard & Poor's se besluit om Suid-Afrika se kredietgradering oor staatskuld te verhoog. Huldeblyke stroom steeds in ná die dood van die oudambassadeur en akademikus, dr. Franklin Sonn.

In deze aflevering van The Dutch Historian Geschiedenis Podcast duiken we in twee uiteenlopende onderwerpen uit de Nederlandse geschiedenis. Lars vertelt over een bijzonder zeventiende eeuws receptenboek gemaakt door een vrouw: Christina Poppinck. Axel vertelt het verhaal van de vergeten pantsertreinen waarmee de Duitsers Nederland binnenvielen. Een van deze pantsertreinen werd door de Nederlanders zelfs vernietigd. Het was een heel klein Nederlands lichtpuntje in de donkere meidagen van 1940. Veel luisterplezier!

Send us a textJakobus 1:12 Gelukkig is die mens wat in versoeking standvastig bly. As hy die toets deurstaan het, sal hy as oorwinningsprys die lewe ontvang wat die Here belowe het aan dié wat Hom liefhet. Ons word omring deur soveel talentvolle mense, nè? Mense wat dinge kan doen wat ons nooit sal kan doen nie; mense wat hoogtes bereik wat ons nooit sal bereik nie; mense wat so perfek lyk, dat dit jou asem wegslaan.Kyk, baie van daardie talent is op een of ander manier deel van hulle; dit spruit uit hul DNS. Ek dink nou aan my vriendin Lorraine, wat ‘n wonderlik begaafde violis is en my ou vriend Laurrie, wat deur sy bediening met liefde en sagmoedigheid ander help om genesing te vind. Daardie mense is in staat tot dinge waartoe ek nooit in staat sal wees nie.En dan ... dan is daar die hele kwessie van versoeking. Jy weet waarvan ek praat, nè? Daardie ander mense lyk almal so voorspoedig en in beheer van alles, terwyl ons ons swakhede ken; ons ons mislukkings sien; ja, ons weet wanneer ons in versoeking gestruikel het en in sonde geval het. Waarom kan ons nie soos hulle wees nie, vra ons onsself af.Maar daar was ook tye toe jy versoeking verduur het; tye toe jy uit 'n diep kennis van die liefde van God vir jou, versoeking weerstaan het; standvastig gebly het ... omdat jy geweet het wat Jesus vir jou gedoen het.Jakobus 1:12 Gelukkig is die mens wat in versoeking standvastig bly. As hy die toets deurstaan het, sal hy as oorwinningsprys die lewe ontvang wat die Here belowe het aan dié wat Hom liefhet.Die dilemma met versoeking is dat wanneer dit oor jou pad kom, dit baie lekkerder voel om daaraan toe te gee, as om dit te weerstaan. Maar, my vriend, hier is die waarheid. Jy hoef nie ‘n wonderlike talent van een of ander aard te hê nie, solank jy  standvastig kan bly wanneer jy nie lus het nie, om die kroon van die lewe te ontvang wat die Here belowe het. Staan vas!Dis God se Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Behind the Scenes van Emotioneel Vastgebonden. In deze aflevering ben ik in gesprek met Timo Marcus, de stille kracht achter de vorm, de structuur en de richting van ons boek.Krijg een diepte-inkijk achter de schermen: • hoe het boek écht tot leven kwam • welke keuzes bepalend waren in het creatieve proces • en hoe de samenwerking tussen Timo, Jaldhara en mij zich ontwikkeldeEen open, eerlijk en inspirerend gesprek over visie, vakmanschap en de rauwe werkelijkheid van een boek schrijven dat levens raakt.

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

Geven voelt veilig. Het is actief, controleerbaar, overzichtelijk.Ontvangen daarentegen vraagt iets wat velen van ons verleerd zijn: overgave.Waarom vinden we het zo lastig om iets aan te nemen — een compliment, hulp, erkenning — zonder het kleiner te maken of direct iets terug te doen?Ontvangen. Ons brein is er niet dol op. Het waarschuwt voor afhankelijkheid, terwijl echte verbinding juist dáár begint. In deze aflevering onderzoek ik hoe we het vermogen om te ontvangen kunnen leren. Met inzichten uit de neurowetenschap, de psychologie én hypnotherapie — waar het onderbewuste leert dat ontvangen niet onveilig is, maar voedend.Een aflevering over controle en overgave, over waardigheid en kwetsbaarheid. En over dat onverwachte moment waarop je voelt: ik hoef het niet allemaal zelf te dragen.

Ons verheug ons ook in swaarkry. 

Die Madlanga-kommissie hoor getuienis aan oor die uitlek van brigadier Julius Mkhwanazi se klagstaat aan die media, Ons praat met die DA se twee nuwe ministers. In Amerika is dit terug-werk-toe nadat die Amerikaanse president, Donald Trump, 'n wetsontwerp onderteken wat die 43-dag lange federale regeringsluiting beeïndig.

ONS has done so many things to change the way we look at alternative public safety initiatives, and we've done it under the leadership of Director Blakey. Today we connect with Brooke Blakey as she removes her cape, retiring from her role at ONS. We are laughing, crying and looking back on the successes of the ONS office before she embarks on her new beginnings, and we move forward as an office. Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

Die MK-party vra hulp om sy vasgekeerde lede in Oekraïne te bevry. 'n Nuwe entstof teen cholera word plaaslik ontwikkel. Ons bespreek vanmiddag se mediumtermyn-begrotingsraamwerk.

Ons word deur genade en geloof gered. 

Ons nader vinnig die einde van die jaar, wanneer baie werkers hul jaarlikse verlof neem en ook hul bonusse ontvang. Werknemers is geregtig op ten minste vier weke betaalde vakansieverlof vir elke 12 maande diens, volgens die Arbeidswet. Die betaling van jaarlikse bonusse is 'n algemene praktyk in die meeste arbeidsektore, insluitend landbou, alhoewel dit nie deur die Arbeidswet voorgeskryf word nie. Danie van Vuuren, die uitvoerende hoof van die Landbouwerkgewersvereniging verduidelik waarom bonusse betaal moet word as dit 'n gereelde instelling is.

In Episode 50, the season finale of Season 5 of Driven by Data: The Podcast, Kyle Winterbottom was joined by James Benford, Director General of Surveys, Economic and Social Statistics at Office for National Statistics, where they have a candid discussion regarding the turnaround job at hand after recent public scrutiny and high-profile errors.They dig into what went wrong, the impact on trust, and how new leadership is refocusing priorities, rebuilding quality, and resetting culture, plus more, which includes;How a turnaround mandate is reshaping ONS culture, leadership, and structure after the June review.Why transparent acknowledgment and correction of high-profile errors is central to rebuilding trust.How grand tech ambitions drift without clear use cases and why that must change.Why building a single data platform without a clear use case became a costly lesson in purpose-led design.How ruthless focus and prioritisation are creating space for excellence in core statistics.Why survey response rates are falling globally and how ONS is adapting to the new reality.How digital-first, user-centred survey design can lift completion and reduce bias.How alternative data sources add power and why third-party data quality and governance matter.Why multidisciplinary teams are non-negotiable.How recognising data and AI as economic assets will reshape national accounting.Why GenAI and ML can raise quality while saving time.How “Stats GPT” style access can make official statistics easier to find, query, and use.Find more information on the general reset underway at the ONS, and the detail on the statistics and the surveys discussed in this episode.If you wish to provide feedback on what ONS is currently doing, please use this mailbox:

Send us a textMatteus 4:4 Maar Hy antwoord: “Daar staan geskrywe: “'n Mens leef nie net van brood nie maar van elke woord wat uit die mond van God kom.” Stel jou vir 'n oomblik voor dat jy honger ly. Sê nou, jy het weke laas geëet. Jy is besig om dood te gaan, jou liggaam wil nie meer reg funksioneer nie. Die lyding is onuitspreeklik. So, wat sal jy doen om kos in jou maag te kry? Instinktief is die antwoord dat ons omtrent enigiets sal doen om kos te kry. Toe Jesus veertig dae en veertig nagte sonder kos in die woestyn was, het die duiwel gekom en Hom versoek om sy lyding in sy eie krag te beëindig. Die duiwel, sê selfs vir Jesus: Jy is die Seun van God. Jy kan dit doen, man!As jy onder dieselfde druk sou verkeer, en die mag sou gehad het om klippe in brood te verander, sou jy die duiwel self gehoorsaam het? Hoekom nie? Wat is verkeerd daarmee?Ons emosies is 'n groot deel van wie ons is. Ons kan dit nie ontken nie. Soms dien hulle ons. Ander kere kan hulle ons in verskriklike moeilikheid laat beland, veral, wanneer ons swaarkry. 'n Emosionele besluit wat op die ingewing van die oomblik geneem word, kan 'n magdom van probleme veroorsaak. Maar kom ons kyk hoe Jesus gereageer het:Matteus 4:4 Maar Hy antwoord: “Daar staan geskrywe: “'n Mens leef nie net van brood nie maar van elke woord wat uit die mond van God kom.”Jesus wys dat Hy sy Vader gehoorsaam en dat Hy nie sy lyding sal beëindig wanneer die duiwel dit voorstel nie. Wanneer jy die Woord van God hoor, keer Hy dat jy in daardie moeilike situasies van die spoor afdwaal; daardie tye wanneer jy die risiko loop om slegte emosionele, ingewing-van-die-oomblik besluite te neem.Soos iemand eenkeer gesê het, as jy nie geestelik gevoed word nie, dan sal jy emosioneel gelei word.Dis God se Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

In The People vs. the Golden State Killer, Thien Ho, the current District Attorney of Sacramento, recounts his harrowing and exhilarating experience as the lead prosecutor responsible for capturing and prosecuting Joseph DeAngelo. Referred to at various times by law enforcement and the media as the Visalia Ransacker, the East Bay Rapist, the Original Nightstalker, and finally the Golden State Killer, DeAngelo, a former policeman, is widely considered “one of the most notorious serial predators in American history.Ho's book is the first official account of how the Golden State Killer was apprehended and put behind bars for life. Ho led an elite team of law enforcement from six California prosecutor's offices, using a newly developed tool known as “investigative genetic genealogy” to connect DeAngelo to multiple cold cases stretching back nearly a half century.Many previous narratives about DeAngelo, including two bestselling books and multiple documentaries, focused largely on the killer and his heinous crimes. This book not only provides hundreds of facts and details never revealed to the public about the Golden State Killer's crimes, it also presents the real-life story of the people who worked tirelessly to bring DeAngelo to justice. It also offers the unprecedented authorized perspective of three survivors of DeAngelo's crimes who courageously turned their pain into empowerment and activism. A portion of the book's proceeds will be donated both by the author and Third State Books to Phyllis's Garden, a nonprofit advocating for victims' rights begun in honor of a GSK survivor.The People vs. the Golden State Killer also recounts Ho's fascinating personal journey, from escaping communist Vietnam with his family as a child to working his way up from an internship to an elite homicide division and eventually becoming one of only ten Asian American district attorneys out of 2,400 nationwide. THE PEOPLE vs THE GOLDEN STATE KILLER: Sacramento District Attorney—Thien Ho

Deze week stormt PSV langs AZ in windstil Alkmaar, geven wingbacks vleugels aan de Eagles en is het Mission Grimpossible bij Ajax. Verder zet de schokeffect-Guardiola zijn reeks door, trekt de kleinste Dick aan het langste eind, en hebben we helaas een brilstandprimeur.Deze week niet met de broertjes maar GIJS, SNIJBOON, PEPIJN en geregistreerd partner van de show FRESIA COUSIÑO ARIAS.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Talle vrae oor bewerings dat die China 'n halfmiljard rand spandeer om een van die weermagbasise op te knap. Ons bespreek die woelinge in die DA oor kabinetskuiwe. Duduzile Zuma-Sambudla vandag in die hof op aanklagte van aanhitsing tot terrorisme en openbare geweld.

Ons kan alleenlik gered word deur ons sonde te erken en te bely. 

Dames, heren, Patrick: welkom bij 90 minutes! Ons panel heeft naar goede gewoonte zijn bifocale lenzen aangedaan om met een scherp oog naar de fases van afgelopen weekend te kijken en heeft zijn glazen bol opgeblonken voor weer tal van visionaire uitspraken. Doen dat deze week: Sam, Filip, Tuur, Daan en ook Gilles is opnieuw van de partij na enkele weken op Love Island.

"I think we really need to push more of our oncology nurses to get into elected and appointed positions. So often we're looking at health positions to get involved in, and those are wonderful. We need nurses as secretaries of health, but there are others. We as nurses understand higher education. We understand environment. We understand energy. So I think we look broadly at, what are positions we can get in? Let's have more nurses run for state legislative offices, for our House of Representatives, for the U.S. Senate," ONS member Barbara Damron, PhD, LHD, RN, FAAN, told Ryne Wilson, DNP, RN, OCN®, CNE, ONS member and member of the ONS 50th anniversary committee, during a conversation about the future of oncology nursing advocacy and health policy. Wilson spoke with Damron and ONS member Janice Phillips, PhD, RN, CENP, FADLN, FAAN, about how ONS has advanced advocacy and policy efforts over the past 50 years and its approaches for the future. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: ONS 50th anniversary series Episode 229: How Advocacy Can Shape Your Nursing Career ONS Voice articles: Oncology Nurses Take to Capitol Hill to Advocate for Cancer Care Priorities Our Unified Voices Can Improve Cancer Survivorship Care With Voices Amplified by ONS, Oncology Nurses Speak Out for Patients and the Profession on Capitol Hill NOBC Partnerships Advance Nurses' Placements on Local and National Boards Nursing Leadership Has Space for You and Your Goals ONS courses: Advocacy 101: Making a Difference Board Leadership: Nurses in Governance Oncology Nursing Forum articles: Nurses on Boards: My Experience on the Moonshot Strengthening Oncology Nursing by Using Research to Inform Politics and Policy ONS Center for Advocacy and Health Policy Current ONS position statements Connie Henke Yarbro Oncology Nursing History Center Campaign for Tobacco-Free Kids Cancer Moonshot National Cancer Policy Forum National Council of State Boards of Nursing APRN Roundtable National Patient Advocate Foundation Nurses on Boards Coalition One Voice Against Cancer Patient Quality of Life Coalition Robert Wood Johnson Foundation Health Policy Fellows To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Phillips: "I think that there are so many pressing issues, but I'm going to start with any kind of threats or legislation that's poised to take away safety-net resources. It's really going to set us back because we all know that, particularly for minorities and certain other underserved populations, they have experienced poor cancer outcomes for a variety of reasons, variety of socioeconomic reasons, lack of access to quality screening resources—you name it. When you take away those safety net resources and take away resources for people who are already underserved, uninsured, or underinsured, it also jeopardizes their ability to get proper screening, get proper follow-up, have access to state of the art cancer services. I think the lack of affordability of health care is a problem that continues to challenge us, whether you on Medicaid or whether you have limited insurance." TS 10:16 Damron: "Because ONS is so grounded in science and research—we're not just a clinical organization; we're grounded in scholarship, science, research, and publication—we're able to take this vast network of strong clinicians [and combine it] with amazing scientists. … We've had some amazing scientists come out of ONS; some of the leading nurse scientists of all time were also oncology nurses. So by combining this, we're able to make a difference at the state and federal level. So the advocacy work that I've been involved in, state and federal levels, really involved working with the ONS staff involved with advocacy and those scientists and clinicians who brought that expertise." TS 18:19 Phillips: "I think expanding the work around multiculturalism in oncology will always be important. Are there any new partnerships or avenues that ONS can reach out to or explore? Maybe there are other specialty organizations or groups—and not always necessarily nursing— because as we think about the determinants of health, we think about things like health and all policies. Maybe there are other disciplines or other specialties that we need to embrace as we launch our agendas." TS 23:28 Damron: "As nurses, just our basic nursing training, we get these skills—we see a problem, we identify the problem, we assess what we're going to do about it, we do it, and then we evaluate what we did. Does that work or not? That's how you make policy. So we were all trained in this. Then what you bring on top of that are oncology nursing experience, whether it's clinical, whether it's research, whether it's teaching, practice, etc. Those continue to refine those skills that are basic to us as nurses. We have this built-in skill set, and we need to own it and understand it." TS 30:25

Richmond, California used to be called America's “Murder Capital”. But when city leaders chose a different path the city's gun violence problem dramatically declined. DeVone Boggan and UC Berkeley's Jason Corburn join Claudia to discuss their new book “Advancing Peace”, which chronicles their efforts to reduce gun violence in Richmond and other cities by focusing on those most likely to pull the trigger. Boggan and Corburn make a case for an approach to gun violence interruption grounded in deep mentorship, community investment and healing and accountability. We discuss:The book's core ideas: ending urban gun violence with redemptive loveHow public health overlooks community strengths by fixating on riskWhy Richmond's Office of Neighborhood Safety sits in government - but outside policingDeVone says that the greatest demonstration of this approach has always been Richmond: “From the moment we implemented the Peacemaker Fellowship in 2010, within 18 to 24 months after we did that, there were dramatic, precipitous reductions in gun violence… Our argument has been [that] when you get the right people to get at the right people the right way over a long period of time, here's living proof and demonstration of what can happen…In 2014, we achieved a 40 year low in gun violence [in Richmond].” Relevant LinksRead Jason and DeVone's book “Advancing Peace: Ending Urban Gun Violence through the Power of Redemptive Love”Listen to an episode from our archives with Megan Ranney on gun violence as a public health issueCheck out Richmond, California's Office of Neighborhood SafetyRead more about Jason Corburn's work at UC BerkeleyGet more information on DeVone's organization Advance PeaceAbout Our GuestsDeVone Boggan serves as Founder and CEO of Advance Peace. Advance Peace interrupts gun violence in American urban neighborhoods by providing transformational opportunities to young men involved in lethal firearm offenses and placing them in a high-touch, personalized fellowship. By working with and supporting a targeted group of individuals at the core of gun hostilities, Advance Peace bridges the gap between anti-violence programming and a hard-to-reach population at the center of violence in urban areas, thus breaking the cycle of gun hostilities and altering the trajectory of these men's lives. DeVone is the former Neighborhood Safety Director and founding director of the Office of Neighborhood Safety (ONS) for the City of Richmond, California. The ONS is a government, non-law enforcement agency that is charged with reducing firearm assaults and associated deaths in Richmond. Under his leadership as Neighborhood Safety Director, the city experienced a 71% reduction in gun violence between 2007 when the office was created and 2016. His work with ONS has been recognized in national publications and media, including the New York Times, Mother Jones, The Nation, Detroit Free Press, The Washington Post, TIME Magazine, PBS NewsHour, NPR, NBC Nightly News, ABC Nightline, CNBC, MSNBC, and CNN. Prior to his

President Cyril Ramaphosa sê die RNE is verenig en sterk - Ons praat met RNE-vennote wat die tweedaagse vergadering bygewoon het. Die stof het nog nie gaan lê oor die Nie-in-my-naam-veldtog nie - ons voer 'n debat met twee opponerende partye. Ons bespreek die Proteas se eerste eendagstryd vanmiddag teen Pakistan.

Deze week zitten SNIJBOON, TIM, en GIJS niet alleen aan tafel, maar YANNICK VAN DE VELDE is aangeschoven om de vierde zetel te vullen. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Bendegeweld vlam weer op, maar hierdie keer in Reigerpark aan die Oos-Rand. Dertien verdagtes sal na verwagting vandag in die hof op Heilbron verskyn in verband met 'n plaasmoord. Ons praat oor 'n moontlike regeringsverandering in KwaZulu-Natal.

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

The Minnesota Justice Research Center is a nonprofit, nonpartisan organization that partners with Minnesota's public safety and legal systems on our policies, programs, and strategic plans. Listen in on this episode with Justin Terrell and Katie Remington Cunningham as they tell us about how their work with ONS and other public safety partners impact community. Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

In CI News this week: The Office for National Statistics cuts ties with Stonewall amid accusations it fell prey to the lobby group's pro-trans ideology, Sheffield University comes under fire for warning students about ‘graphic' scenes in the Bible, and gambling firms are taken to task by the advertising regulator for airing adverts that appeal to children. You can download the video via this link. Featured stories ONS exits Stonewall scheme after census' dodgy trans data Sheffield Uni slaps ‘violent' trigger warning on Gospel accounts Top psychiatrist warns teenagers against ‘stewing brains in cannabis soup' Betting ads with child appeal ‘irresponsible', regulator rules

Die burgemeester van Saldanha is onstoke omdat die ANC 'n aandklokreël ingestel het, wat beoog om kinders te beskerm. 'n Nuwe konstruksie-aksieplan van die Departement van Openbare Werke is daarop gemik om tenderpreneurs vas te vat. Ons praat oor dobbel - waneer is dit 'n euwel, en wanneer net onskuldige vermaak?

Wat zit er vandaag in De 7? Ons land heeft voor het eerst buitenlandse investeringen gedeeltelijk tegengehouden, omdat ze onze economische veiligheid bedreigden. Hoe zit dat precies? De Brusselse formateur David Leisterh gooit de handdoek in de ring. Waarom? En geraakt de Brusselse formatie ooit nog uit het slop? BNP Paribas krijgt opnieuw klappen op de beurs. De Franse grootbank heeft last van kakkerlakken (?) Presentatie: Roan Van EyckProductie: Lore AllegaertSee omnystudio.com/listener for privacy information.

Die wêreld hou jou oë, ore en hart besig. Dis likes, shares en eindelose scrolls. Maar diep binne jou, onder al die geraas, lê daar 'n honger — jou gees weet: daar is meer… Nuwe navorsing wys wat antieke geloof nog altyd geweet het: dat ons gebou is met 'n bewussyn vir die ewige — 'n ingeboude verlange na sin en betekenis, vryheid en eenwording met God. En tog, in ons moderne wêreld, raak daardie geestelike sintuie afgestomp. Ons hoor, maar luister nie. Ons kyk, maar sien nie.Ons sing, maar voel nie meer nie. Hierdie Sondag ontdek ons saam hoe om weer daardie innerlike sintuie te herkalibreer — Ons gaan leer om Hom te sien, hoor, proe, ruik en voel — met die oë van die hart, die ore van die siel, en die aanraking van die Gees. Hierdie boodskap gaan jou help onderskei tussen emosie en openbaring, tussen die “gevoel van iets” en die werklikheid van Iemand — die Drie-enige God wat sigbaar word vir diegene met geopende oë. #Openbaring #Herlewing #Verkwikking #Vernuwing #GeestelikeDiepte

Die meeste mense in die Westerse wêreld hou nie van enige beperkinge nie. Ons wil ons eie lewens lei, op ons eie manier. Grense is nie tralies nie; dit is die randstene van wysheid. Soos sypaadjies 'n pad veilig hou, 'n skildery eers tot sy reg kom in 'n raam, en musieknote jou gemoed streel wanneer dit in 'n bepaalde ritme en akkoord is. Sonder grense raak liefde goedkoop, werk 'n afgod, en plesier leeg. Hierdie generasie wil alles ervaar, vrees om iets te mis (FOMO - "fear of missing out"), met almal vriende wees, plesier najaag en bly lekker voel in die proses.In hierdie preek gaan ons kyk na die belangrikheid van GODDELIKE HEILIGE grense in ons lewens. Ons gaan ondersoek hoe God se grense ons nie beperk nie, maar ons bevry om in sy volheid te leef. Kom ons ontdek saam hoe ons deur die aanvaarding van God se grense, 'n lewe van oorvloed en vreugde kan lei. 

Deze week zitten PEPIJN, TIM, ROGIERPABLO en GIJS aan tafel voor een nieuwe aflevering van De Derde Helft! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

“This was a panel of subject matter experts of various nurses and pharmacists. We often found common ground but also discovered new ideas, different touchpoints, and key junctures along that oral anticancer medication journey. For example, the pharmacists were able to share their insights into their unique workflows within their practice setting. What resulted is a resource that truly reflects that collaborative effort between the disciplines,” ONS member Mary Anderson, BSN, RN, OCN®, senior manager of nursing membership and professional development at the Network for Collaborative Oncology Development and Advancement (NCODA) in Cazenovia, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS. Anderson spoke with Weimer and Kris LeFebvre, DNP, RN, NPD-BC, AOCN®, oncology clinical specialist at ONS, about the Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation, a project created as a collaboration between ONS and NCODA. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD contact hours. ONS Podcast™ episodes: Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice articles: As Institutions Establish Oral Agent Workflows, Savvy Educators Help Nurses Apply Them to Practice Maintain Oral Adherence With ONS Guidelines™ The Oncology Nurse's Role in Oral Anticancer Therapies ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC®Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Implementation of an Oral Antineoplastic Therapy Program: Results From a Pilot Project Oncology Nursing Forum articles: Domains of Structured Oral Anticancer Medication Programs: A Scoping Review Interventions to Support Adherence to Oral Anticancer Medications: Systematic Review and Meta-Analysis ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications Other ONS resources: ASCO/ONS Antineoplastic Therapy Administration Safety Standards Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library Drugs@FDA Hematology/Oncology Pharmacy Association Oral Chemotherapy Collaborative National Comprehensive Cancer Network homepage NCODA homepage Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode LeFebvre: “There are five different elements to the care compass itself. The first is called the OAM [oral anticancer medication] workflow analysis tool. ... This [tool] allows an OAM program to really study where their processes are. Where are the gaps in the process and where might their patients be at risk? It's something that you can use within your setting to analyze your current processes and see where you can strengthen them. The second tool is something focused on patient and caregiver education. This includes a lot of information about what should be taught, how it could be taught, the best timing and so forth, according to the literature. ... The third tool is an assessment and grading tool. It's a fun tool that approaches symptom management using the Common Terminology Criteria for Adverse Events grading tool. ... The fourth tool is a specialty pharmacy and patient assistance contact directory template. This is a spreadsheet that can be used by anyone navigating patient care with OAMs to keep track of their professional contacts. ... The final [tool] is the OAM adherence blueprint. This has a lot of important information on adherence, methods to assess adherence, and calculate adherence rate.” TS 7:15 LeFebvre: “Interprofessional collaboration is so essential just in day-to-day care, and OAM care is no different in that regard. Oncology nurses work in so many different settings and their role may be very different even if they have the same title. You can have OAM navigation that is completely handled in the pharmacy. I've talked with nurses who have said, ‘We don't even touch it.' But they do. Because when a patient has a combination regimen, they might have an infusion regimen that goes along with an oral therapy. Or that patient might just know that infusion room nurse so much better and they feel more comfortable [contacting them] when they have a side effect from their oral therapy. So, infusion nurses need to be aware of what the patients are on and what the potential side effects are.” TS 14:14 Anderson: “The resource for OAM education that we created is literally a blueprint of many resources out there to help nurses, pharmacists, and oncology professionals educate their patients on taking OAMs. ... [The OAM Care Compass] also helps with communication channels. It helps knowing that all the documentation is occurring and when everybody is documenting within their role and according to those key touchpoints, there's less opportunity to lose track of your patients because we know what's happening.” TS 16:33 Anderson: “I think the biggest misconception we see is that people think taking OAMs is easier than infusion therapies. And while it's true that OAMs do offer significant benefits such as the convenience and the ability for patients to take their medication at home, we are also placing a huge burden on our patients. They need to navigate that very complex health system to obtain their medication and understand their treatment plan and adhere to that precise regimen. Additionally, we are seeing more and more complex treatment regimens with combination therapies, which further increases the need for that early and ongoing education, monitoring, and support.” TS 20:38

Today The Standard can reveal a new interactive map that pinpoints London's violent crime hotspots, as latest figures show the capital still accounts for almost a third of knife offences in England and Wales. Billy Gazard, of the ONS, said the data for police-recorded crime “paints a mixed picture”, adding: “Homicide and offences involving knives and guns have all fallen in the past year. While shoplifting continues to rise year on year, there are signs the rate of increase in reporting of these offences is slowing.” The Standard's Crime Correspondent Anthony France is here with the latest. And in part two, The Standard's Culture Writer India Block joins us to discuss Lily Allen's new album, West End Girl. It's the pop star's first album in seven years and offers a lyrical takedown of her ex, David Harbour, that does not pull any punches. Hosted on Acast. See acast.com/privacy for more information.

PEPIJN is terug van weggeweest. De kinderen liggen in bed dus kan hij weer aanschuiven bij de Derde Helft om weer een lekker over de leukste voetbalcompetitie van de wereld te praten. Dat doet hij niet alleen, maar samen met TIM, ROGIERPABLO en SNIJBOON. Hopelijk lacht dit viertal niet te veel, anders wordt de vriendin van ROGIER boos. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

According to the Office for National Statistics, the number of births in the UK continues to fall. Experts are even talking about a “baby bust”, the opposite of the “baby boom”, to describe these statistics, which have reached the lowest level since records began in 1938. One explanation for this could be that people are having children later than previous generations, leaving them with a reduced fertility window. In 2020, the Office for National Statistics notes that the average age at which women become mothers is 30, compared with 26 in 1975. In addition to this, the latest ONS birth data, released in 2020, reveals that 28% of women have their first child after the age of 30 and 5% after the age of 40. Can you run into problems if you want to get pregnant after the age of 30? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: Could intentional lazy parenting foster your child's independence? What causes tocophobia, the fear of pregnancy and childbirth? ⁠Why do children have imaginary friends? A podcast written and realised by Amber Minogue. First Broadcast: 27/2/2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

“It started out by doing a kind of a white paper that we called Imperatives for Quality Cancer Care. Ellen Stovall, our CEO [of the National Coalition for Cancer Survivorship] at the time, gave this report to Dr. Richard Klausner, who was the head of National Cancer Institute at the time. He called Ellen immediately and said, ‘Why are we not doing something about this?' Within one year, we had the Office of Cancer Survivorship at NCI,” ONS member Susan Leigh, BSN, RN, told ONS member Ruth Van Gerpen, MS, RN-BC, APRN-CNS, AOCNS®, PMGT-BC, member of the ONS 50th anniversary committee, during a conversation about her involvement in cancer survivorship advocacy. Van Gerpen also spoke with ONS members Deborah Mayer, PhD, RN, AOCN®, FAAN, and Timiya S. Nolan, PhD, APRN-CNP, ANP-BC, about the history and future of cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 91: The Seasons of Survivorship Episode 49: The Cancer Survivorship Conundrum ONS Voice article: Our Unified Voices Can Improve Cancer Survivorship Care ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Survivorship Care: More Than Checking a Box The Missing Piece of Survivorship: Cancer Prevention Oncology Nursing Forum articles: Patient Perceptions of Survivorship Care Plans: A Mixed-Methods Evaluation Survivorship Care Plans: Health Actions Taken and Satisfaction After Use ONS Survivorship Learning Library Rehabilitation of People With Cancer: Position Statement from the Association of Rehabilitation Nurses (ARN) and endorsed by the Oncology Nursing Society Connie Henke Yarbro Oncology Nursing History Center American Cancer Society Survivorship resources Cancer Survivors Network Cancer Nation (formerly National Coalition for Cancer Survivorship) Cancer Survival Toolbox Imperatives for Quality Cancer Care: Access, Advocacy, Action, and Accountability (white paper) National Cancer Survivors Day Foundation New England Journal of Medicine article: Seasons of Survival: Reflections of a Physician With Cancer by Fitzhugh Mullan To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Leigh: “Another way that [National Coalition of Cancer Survivorship] got very involved with looking at how we keep this information coming and how we really share care with our outside physicians is the development of survivorship care plans. And then we also hoped that we would see more survivorship clinics by now. But between trying to get people to develop care plans and clinics, it's been like pulling teeth. It has been very difficult. And a lot of this struggle to get this going has been, first of all, there isn't enough money to do this. There isn't enough time for immediate staff to take these on, and we just don't have enough staff as it is now. And survivorship is not a moneymaker, so it's just something that has to be done kind of on the side.” TS 11:54 Mayer: “When I became ONS president in the '80s—I was the fourth ONS president—we were given a cancer grant to do something with our presidency. And that was when I really wanted to bring attention to rehabilitation as a means to address cancer survivorship issues because we had a very ‘treat 'em and street 'em' attitude. We gave you your treatment, and we sent you home, and you had to figure out the rest. And there wasn't a lot of knowledge or support to help you put your life back together again afterwards. And so in that process, it was an interdisciplinary group of professionals that tried to come up with what was an appropriate position statement because ONS was just starting to do position statements. And so we developed a first position statement on cancer rehabilitation to address survivorship issues in like 1987 to '89.” TS 17:15 Mayer: “When I went back to school for my PhD, I did my dissertation on health behaviors of cancer survivors and realizing the huge gap in the care that they were getting for anything other than their cancer. We were still focused on their tumor and on treating their tumor. But we were missing the picture that if the cancer didn't kill them, their heart disease would, and they would develop diabetes and other things. … But as people started living longer and longer, we were missing all these other chronic illnesses that would contribute to their quality of life and overall lifespan. So my dissertation put me on a different path, and I think the second part of my career was really focusing on instead of just relieving suffering and the quality of life issues, really looking at cancer care delivery and how we could do a better job of doing the team of teams that people needed to have their issues addressed.” TS 19:34 Nolan: “I ended up having my first permanent role on a hematology-oncology unit at the University of Alabama at Birmingham. And there, I literally saw patients who were fighting for their lives. And despite the severity of their illness, they wanted more than just survival. They wanted to have meaning. They wanted to have dignity. They wanted to have impact with the time that they had left, whatever it was. And so those experiences planted a seed in me. And that seed was that cancer care must extend beyond treatment and we need to embrace, really, quality of life.” TS 23:31 Leigh: “I was not the researcher. I was not the major writer. I was not the identifier of a lot of the risk factors. But I spread the seed. I took all that information from different sources and shared that with all of the audiences that I spoke to. So I was called a seed spreader, kind of the Johnny Appleseed of oncology nursing at that particular time. And then once we saw academia step in and say, ‘We need to get good data about what's going on here,' … then my stories and stories from survivors started decreasing and the presentations were given more from the academic standpoint.” TS 34:41 Nolan: “I really believe in community, academic, government, and industry approaches to survivorship as well. We can no longer operate in silos. We really need to learn how to walk across the aisle, build bridges as we can so that we can do this work together because we know that communities bring lived wisdom and context. And academicians bring the research and the ability to create the evidence. The government brings policy and public health infrastructure, and certainly industry brings innovation and scalability. But also in this new paradigm that we find ourselves in, the industry may also bring the dollars to be able to help us to do even more work.” TS 43:45

As Rachel Reeves approaches a tricky budget, her job has got that much harder. Some of our most fundamental economic data, statistics that policymakers are used to accepting at face value, suddenly have major question marks over their accuracy.The UK's top stats agency, the Office for National Statistics, finds itself under considerable pressure as falling response rates to its surveys leave politicians flying blind. David Aaronovitch asks what this means for government decisions and how the ONS can rebuild confidence in its most vital statistics.Guests: Georgina Sturge, research affiliate at the Migration Observatory at the University of Oxford Professor Denise Lievesley, former Principal of Green Templeton College, Oxford Chris Giles, economics commentator at the Financial Times. Peter Lynn, Professor of Survey Methodology at the University of EssexPresenter: David Aaronovitch Production co-ordinator: Maria Ogundele Producers: Nathan Gower, Kirsteen Knight, Cordelia Hemming Studio engineer: Duncan Hannant Editor: Richard Vadon

“Chemotherapy-induced alopecia does cause a lot of stress. It's associated with lower quality of life. Scalp cooling may really help improve quality of life. Some studies have shown that women in the scalp cooling group felt less upset about losing their hair and less dissatisfied with their appearance compared to the women in the control group that didn't receive any scalp cooling. So a lot of these studies are showing it does have a very positive impact on psychosocial feelings and side effects in relation to overall cancer treatment,” ONS member Jaclyn Andronico, MSN, CNS, OCN®, AOCNS®, clinical nurse specialist at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about chemotherapy-induced alopecia and scalp cooling. The advertising messages in this episode are paid for by Paxman. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ Episode 250: Cancer Symptom Management Basics: Dermatologic Complications ONS Voice articles: Diagnose and Manage Dermatologic Toxicity Secondary to Immunotherapy Follow the Evidence When Using Scalp Cooling for Cancer Alopecia Reimbursements Are Making Scalp Cooling More Accessible for Patients With Cancer The Case of the CIA-Combatting Combination ONS Voice oncology drug reference sheets: Docetaxel Doxorubicin Hydrochloride Sacituzumab Govitecan-Hziy ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity Clinical Journal of Oncology Nursing articles: Chemotherapy-Induced Alopecia: Examining Patient Perceptions and Adherence to Home Haircare Recommendations Scalp Cooling: Implementing a Cold Cap Program at a Community Breast Health Center Scalp Cooling: Implementation of a Program at a Multisite Organization Oncology Nursing Forum articles: Effectiveness, Safety, and Tolerance of Scalp Cooling for Chemotherapy-Induced Alopecia The Effect of Chemotherapy-Induced Alopecia on Distress and Quality of Life in Male Patients With Cancer ONS Altered Body Image Huddle Card Journal of Market Access and Health Policy article: Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia HairToStay Paxman patient assistance program Rapunzel Project To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Some of the classes that are high risk for chemotherapy-induced alopecia can include antitumor antibiotics, such as doxorubicin, epirubicin; antimicrotubule drugs, such as taxanes like docetaxel, paclitaxel; alkylating agents such as cyclophosphamide. The lower risk alopecia-causing chemo agents are the antimetabolite classes, which a lot of people know as gemcitabine or fluorouracil. We also are seeing patients experience some degree of alopecia with a drug called sacituzumab govitecan, which is an actual antibody–drug conjugate.” TS 2:09 “Scalp cooling is approved for solid tumor patients. Patients receiving chemotherapy agents, as we discussed before, with that high incidence of chemotherapy-induced alopecia really should be considered for scalp cooling as long as they don't have certain contraindications. Some contraindications do exist for these populations. Those are patients that have cold agglutinin diseases, cryoglobulinemia, cryofibrinogenemia, and any cold sensitivity issues. Patients also with abnormal liver functions are not suggested to receive scalp cooling because their liver function is associated with the metabolism of the drug agent. It's also not recommended for patients with hematologic malignancies who are higher risk for cutaneous metastatic disease or failed chemotherapy and even reduced survival rates.” TS 9:23 “Overall, scalp cooling has a good tolerance, but it's important to be aware that scalp cooling can be uncomfortable for some, and it isn't always tolerated by some patients. Patients have reported side effects such as headaches, dizziness, chills, cold sensations, scalp pain, head discomfort, and even claustrophobia. Among these, the most common is the cold feeling and headaches. So when caring for patients that undergo scalp cooling, the nurses really should recognize the patient's feelings and help relieve that discomfort with position changes, prophylactic painkillers such as [acetaminophen] or [ibuprofen] if they're allowed to take that, additional warm blankets. Even antianxiety medications can really help, especially if that claustrophobia feeling is there. So collaborating with that team, the doctors, the nurse practitioners, just to be aware that if the patient's not comfortable during this treatment of scalp cooling, they should have those things on board prior to starting.” TS 12:23 “A lot of primary education points for nurses to review with patients is explaining the financial reimbursement process and assistance options—collaborating with that financial department within your institution. Also discussing the efficacy of the scalp cooling and the tolerability of it as well. I don't know if patients are always aware of the feeling of the cold—really warning them, letting them know what they're going to experience while in the chair attached to that cooling machine.” TS 18:55 “Nurses, we're at the forefront of scalp cooling, and we manage a lot of this area that comes with the service. They are managing, the coordination of the care, the education. They're assisting with that financial discussion and collaborating with the financial department. The symptom management—they're helping make the patients feel more comfortable with the symptoms of scalp cooling. They are the real deal here, so they are the best in helping with the situation. Nurses should be really familiar with the efficacy, again, and the tolerability, the contraindications, the side effects, and the costs and even the access for scalp cooling.” TS 20:57